This session highlights the critical role of intracoronary imaging in evaluating acute coronary syndromes (ACS). It discusses the management of complex lesion morphologies involving calcium and thrombus, the diagnostic power of OCT in decision-making, challenges beyond angiography in right coronary artery pathology, and the identification of...

This session reviews key sub-studies from major TAVI trials that extend beyond primary endpoints to provide a deeper understanding of valve performance and patient outcomes. It covers comparisons between balloon-expandable and self-expanding valves, long-term real-world data on the Myval valve, echocardiographic outcomes, composite endpoint analyses, and...

This session focuses on the diagnosis and management of ischemia and angina with non-obstructive coronary arteries (INOCA and ANOCA). It presents safety data from coronary function testing, patient outcomes after comprehensive ischemia assessment, and endotype-specific treatment effects. Further topics include coronary sinus reducer therapy, the impact...

This session highlights new evidence in coronary physiology related to microvascular assessment. Topics include endothelial dysfunction in angina with non-obstructive arteries, the prognostic value of microvascular resistance metrics, natural history studies, and trials aimed at standardizing management of microvascular dysfunction.

There is no doubt that the original Stent for Life initiative had a huge, positive impact on morbidity and mortality in patients with STEMI in Europe. With the global Stent – Save a Life! (SSL) initiative comes the continued spread of the mission to other regions,...

Chiara De Biase provides her take on the FAST III Trial presented by Joost Daemen at ACC.26 in New Orleans. She reviews the comparison between vFFR and FFR, highlighting key findings and their impact on revascularisation strategies.

Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.

The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...

In this article, Ulrich Schäfer explores the evolving landscape of access strategies in transcatheter aortic valve implantation (TAVI). While the transfemoral approach remains the gold standard, a significant proportion of patients are not suitable due to peripheral vascular disease or anatomical constraints.
Drawing on clinical evidence and...

Kalaivani Mahadevan and Fizzah Choudry provide their take on DAPT-SHOCK-MI presented by Zuzana Motovska at ESC Congress 2025 in Madrid.

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)